167 reports of this reaction
0.8% of all OXYMORPHONE HYDROCHLORIDE reports
#16 most reported adverse reaction
WITHDRAWAL SYNDROME is the #16 most commonly reported adverse reaction for OXYMORPHONE HYDROCHLORIDE, manufactured by Amneal Pharmaceuticals LLC. There are 167 FDA adverse event reports linking OXYMORPHONE HYDROCHLORIDE to WITHDRAWAL SYNDROME. This represents approximately 0.8% of all 20,768 adverse event reports for this drug.
Patients taking OXYMORPHONE HYDROCHLORIDE who experience withdrawal syndrome should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
WITHDRAWAL SYNDROME is a less commonly reported adverse event for OXYMORPHONE HYDROCHLORIDE, but still significant enough to appear in the safety profile.
In addition to withdrawal syndrome, the following adverse reactions have been reported for OXYMORPHONE HYDROCHLORIDE:
The following drugs have also been linked to withdrawal syndrome in FDA adverse event reports:
WITHDRAWAL SYNDROME has been reported as an adverse event in 167 FDA reports for OXYMORPHONE HYDROCHLORIDE. This does not prove causation, but indicates an association observed in post-market surveillance data.
WITHDRAWAL SYNDROME accounts for approximately 0.8% of all adverse event reports for OXYMORPHONE HYDROCHLORIDE, making it a notable side effect.
If you experience withdrawal syndrome while taking OXYMORPHONE HYDROCHLORIDE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.